Hippo Holdings Inc. Common Stock (HIPO)

Hippo Holdings (HIPO) meets strict growth stock criteria with soaring earnings, strong sales momentum, expanding margins, and high return on equity.

Wall Street didn't take kindly to financial reports from Axon, Trex, and Warby Parker. Should investors be buying amid the bloodbath?

Hippo Holdings (HIPO) aligns with Louis Navellier's growth investing principles, showing massive EPS growth, rising revenue, and improving margins.

Hippo Holdings (HIPO) reported mixed Q3 2025 results, beating revenue estimates but missing significantly on earnings per share.

Hippo Holdings (HIPO) shows strong technical momentum and accelerating earnings growth, fitting systematic growth strategies. The stock exhibits exceptional relative strength and a confirmed uptrend.

Hippo Holdings (HIPO) reports Q2 2025 earnings beat with $0.65 EPS vs. expected loss, but revenue slightly misses at $117.3M. Shares dip pre-market amid growth concerns.

HIPO stock results show that Hippo Holdings missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Wall Street analysts have yet to discover these three FinTech stocks. Consider ML, NRDS, and HIPO as they're undervalued and ready to surge.

Top small-cap stocks to buy Viking Therapeutics, Celsius and Hippo make waves in the weight loss, energy drink, and insurance tech sectors.

HIPO stock results show that Hippo Holdings missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

HCI Group reported better-than-expected fourth-quarter earnings and revenue late Thursday.